Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Volume Expansion in Children with Shiga Toxin-Producing E. coli Infection to Prevent or Mitigate Hemolytic Uremic Syndrome: Planning a Multinational Randomized Clinical Trial

Award Number: R34AI136783
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2019
PERIOD OF PERFORMANCE END DATE: 06/30/2021

Group Awards By:

View Award Description

Volume Expansion in Children with Shiga Toxin-Producing E. coli Infection to Prevent or Mitigate Hemolytic Uremic Syndrome: Planning a Multinational Randomized Clinical Trial - Project Summary/Abstract Long-term Objectives: To prevent or mitigate the complications of the hemolytic uremic syndrome in children with Shiga Toxin-producing Escherichia coli (STEC) infections. Health-Relatedness of the Project: This study’s goals align with the NIAID’s mission to conduct and support applied research to better treat and prevent infectious diseases. The focus aligns with NIAID’s enteric diseases interest that includes STEC infection. The latter are a priority because of their frequency (265,000 STEC infections annually in the US) and severity as over 35% of these infections are caused by E. coli O157:H7 and 15% of infected children develop the HUS. Specific Aims Despite the conduct of numerous elegant molecular, cellular, and genomic research studies, no safe and effective interventions that reduce the likelihood of severe renal injury after STEC infections have been developed. Recent cohort studies, including several led by our group, suggest that aggressive intravenous volume expansion early in STEC infections could be nephroprotective. However, most North American clinicians continue to rely on reactive care in cases of STEC infection, namely, treating renal and hematologic consequences of STEC injury if and when they occur. Our goal is to conduct a multicenter randomized clinical trial (RCT) to assess the efficacy of intravascular volume expansion in STEC-infected children. In preparation for such trial, the following specific aims are proposed: 1) Finalize the protocol, statistical analysis plan and standard operating procedures to conduct a rigorous, safe, reproducible and generalizable multinational RCT of intravascular fluid expansion in STEC infected children; and 2) To pre- emptively address implementation, feasibility, training, recruitment, financial and ethical issues thereby ensuring the seamless, efficient, safe and successful conduct of the trial.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2019	GOVERNORS OF THE UNIVERSITY OF CALGARY, THE	2500 UNIVERSITY DR NW	CALGARY	AB			CAN	Allergy and Infectious Diseases Research	000	1	11/23/2022	NEW	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = -$10,563 )
2022	2019	GOVERNORS OF THE UNIVERSITY OF CALGARY, THE	2500 UNIVERSITY DR NW	CALGARY	AB			CAN	Allergy and Infectious Diseases Research	000	1	4/22/2022	NEW	-$10,563
														Subtotal = -$10,563

Issue Date FY: 2019 ( Subtotal = $222,699 )
2019	2019	GOVERNORS OF THE UNIVERSITY OF CALGARY, THE	2500 UNIVERSITY DR NW	CALGARY	AB	T2N 1N4		CAN	Allergy and Infectious Diseases Research	000	1	6/18/2019	NEW	$222,699
														Subtotal = $222,699

Grand Total All Awards = $212,136

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Volume Expansion in Children with Shiga Toxin-Producing E. coli Infection to Prevent or Mitigate Hemolytic Uremic Syndrome: Planning a Multinational Randomized Clinical Trial

Award Number: R34AI136783

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2019

PERIOD OF PERFORMANCE END DATE: 06/30/2021

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer